Donor-Derived Memory-like NK Cells for the Treatment of Children and Young Adults with Relapsed AML Following Allo-HCT

Leukemia recurrence is the most common type of treatment failure after allogeneic hematopoietic cell transplantation (allo-HCT) for pediatric AML. We have advanced memory-like (ML) NK cells as a cellular therapy for AML. NK cells differentiated to ML NK cells after stimulation with interleukins-12, -15, and -18 display significantly enhanced anti-leukemia functionality and in vivo persistence. We performed a prospective clinical trial utilizing donor lymphocyte (DLI) and ML NK cell infusions to treat relapsed AML after allo-HCT.

https://www.astctjournal.org/article/S2666-6367(23)01770-0/fulltext?rss=yes

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Thomas Pfeiffer, Clare Zimmerman, Melissa M Berrien-Elliott, Jennifer Foltz, Michelle Becker-Hapak, Carly Neal, Mark Foster, Timothy Schappe, Ethan McClain, Patrick Pence, Sweta Desai, Pamela Wong, David Russler-Germain, Bryan Fisk, Lie Wen-Rong, Jeremy E Tags: 15 Source Type: research